A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Author | |
---|---|
Abstract | :
Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). |
Year of Publication | :
2018
|
Journal | :
Journal of hypertension
|
Date Published | :
2018
|
ISSN Number | :
0263-6352
|
URL | :
http://Insights.ovid.com/pubmed?pmid=29334491
|
DOI | :
10.1097/HJH.0000000000001647
|
Short Title | :
J Hypertens
|
Download citation |